Sir, one question, again, very directionally more qualitative in nature when you made this comment of the US rather opportunities shifting out of China and the customers approaching Neuland to proceed with the molecule. How do we think about the pricing dynamics and the overall cost structure for the business as such? Because at the end of the day, when you are trying to pursue that molecule, you are going to compete with other players also and you're going to, to a certain extent, going to compete with the Chinese pricing as well because that's the benchmark. So how should we think about pricing from Neuland's perspective and industry in general because I think that's going to be something that we'll have to keep in mind, right, for a lot of business that is different from China. So just a thought?
Sure. That's really helpful. Just one clarification, if I may. When you talk about this particular molecule, as an example, shifting out of China, again, from a benchmark perspective, let's say, if you have the biotech company coming to you in the initial stages and you being the primary supplier as compared to the same mo lecule shifting out of China, would there be a material difference? Or is this something that we should not lose our sleep on? Like I understand that over a 3 to 5year period, whatever you're projecting with the particular level of volume, it might not make a very large difference. But let's say, for the initial period of time, is there something we should keep in mind in terms o f a large gap for the pricing perspective?